FOSTER CITY, CA - January 11, 2006 - Applied Biosystems (NYSE:ABI), an Applera Corporation business, announced today that it will now offer its BioMonitor® Service for selected Applied Biosystems/MDS SCIEX mass spectrometers. The BioMonitor Service helps customers maximize system uptime and improve productivity through Applied Biosystems'''' remote monitoring of customers instruments over the Internet. With real-time troubleshooting and problem solving, the service can assist in predicting and preventing instrument failures, improve speed of repairs, reduce the loss of critical samples and reagents, and help ensure the accuracy and quality of results.
The BioMonitor® Service has been available on selected Applied Biosystems genetic analysis instrument for three years and has now been expanded as a service to its Applied Biosystems/MDS SCIEX mass spectrometer customers. This service is available to Applied Biosystems'''' customers as part of the Company''''s BioAssurance® and BioAssurance® Plus Services and is part of the instrument warranty. In addition, Applied Biosystems was recently named among the top "best practice" winners by the Aberdeen Group for excellence in managing and delivering aftermarket services through the BioMonitor® Service.
"We know that data accuracy and instrument productivity are among our customers'''' top priorities and we are pleased to be able to extend our leading-edge BioMonitor® Service to our mass spectrometer customers," said Michael G. Schneider, Division President, Global Services, Applied Biosystems. "This service helps our customers to better manage and improve their laboratory environments, and can significantly improve instrument uptime. Further, we expect to expand our BioMonitor® Service in the near future to provide remote control, diagnostics, and real-time lab optimization and analysis."
"Applied Biosystems is one of the clear market leaders in using the Axeda Device Relationship Management (DRM) solution to enhance they way they deliver service to their customers," said Dale Calder, President and CEO, Axeda Corporation. "Expanding BioMonitor® Service to more product lines enables even more customers to take advantage of the strong benefits that the service delivers."
BioMonitor® Service is currently offered on the API 2000™, 3000™, 3200™, 4000™, and 5000™ LC/MS/MS Systems, and the 3200 Q TRAP®, 4000 Q TRAP®, and QSTAR® XL Hybrid LC/MS/MS Systems. BioMonitor® Service is expected to be offered on the 4700 and 4800 MALDI TOF/TOF™ Analyzers in early 2006.
As a leading supplier of instruments to the life science industry and research community, Applied Biosystems'''' field service organization is responsible for maintaining over 180,000 instrument systems in nearly 100 countries. Applied Biosystems offers a complete suite of service and support products, which includes the superior value-added BioMonitor® service. For more information on Applied Biosystems'''' services offerings please visit: www.appliedbiosystems.com.
About Applera Corporation and Applied Biosystems
Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems'''' products also serve the needs of some markets outside of life science research, which we refer to as "applied markets," such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, CA, and reported sales of nearly $1.8 billion during fiscal 2005. The Celera Genomics Group is focused on discovery, development, and commercialization of diagnostic products as well as leveraging its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and is also seeking to advance therapeutic antibody and selected small molecule drug programs in collaboration with global technology and market leaders. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com.
About MDS Sciex and MDS Inc.
MDS Sciex is the analytical instrumentation and technology solutions division of MDS Inc. MDS Inc. (TSX: MDS; NYSE: MDZ) has more than 8,800 highly skilled people in 27 countries. We provide a diverse range of superior products and services to increase our customers'''' speed, precision and productivity in the drug development and disease diagnosis processes. We are a global, values-driven life sciences company, recognized for our reliability and collaborative relationships as we help create better outcomes in the treatment of disease. Find out more at www.mdsinc.com or by calling 1-800-MDS-7222, 24 hours a day.
About Axeda Corporation
Axeda enterprise software enables a new generation of high-value remote services that maximize the value of the products you sell. Customers benefit from increased uptime and a superior product experience, while manufacturers generate increased revenue and higher customer satisfaction ratings with reduced cost of service delivery.
Axeda solutions include condition monitoring, remote repair, patch management, pay-per-use billing, preventative maintenance, performance optimization and more. These solutions enable companies to grow revenue, reduce service costs, increase customer satisfaction, and manage risk. Leading organizations such as Abbott Laboratories, Cardinal Health, EMC, Kodak Versamark, and Quantum are using Axeda solutions today. For more information about our products, services, and customers visit: www.axeda.com.
Applied Biosystems Forward Looking Statements
Certain statements in this press release are forward-looking and subject to a variety of risks and uncertainties. These may be identified by the use of forward-looking words or phrases such as "believe," "should," and "expect," among others. These forward-looking statements are based on Applera Corporation''''s current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to: (1) rapidly changing technology and dependence on new products; (2) sales dependent on customers'''' capital spending policies and government-sponsored research; and (3) other factors that might be described from time to time in Applera Corporation''''s filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.
For Research Use Only. Not for use in diagnostic procedures.
© 2006 Applera Corporation. All rights reserved. Applied Biosystems, BioMonitor, and Celera are registered trademarks and Applera and Celera Genomics are trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries.
Erin Nolan Smith
Director, Marketing Communications
Vice President, Investor Relations
MDS Inc. Media & Investor
+1 (416)-675-6777 ext. 2695